Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 9/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22005543 | 0.85 | TSHR (0.53) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL22162665 | 0.85 | TSHR (0.53) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL7610543 | 0.83 | TSHR (0.39) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL10477009 | 0.82 | ANPEP (0.48) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL21973637 | 0.80 | ANPEP (0.46) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL18949821 | 0.80 | ANPEP (0.46) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL56311 | 0.79 | ANPEP (0.65) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL727642 | 0.79 | — | — | |
| SCHEMBL18085375 | 0.79 | — | — | |
| SCHEMBL11222798 | 0.79 | ANPEP (0.50) | ANPEPERAP1ERAP2TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330074-A1 | COMPOUNDS AND METHODS FOR TREATING SPASTICITY | LEXICON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2021178612-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2019079119-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-04-25 | — | — | WO | disclosed |
| EP-0994108-B1 | PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6197970-B1 | REACTING WITH SECONDARY OR TERTIARY AMINE; DEBLOCKING, DEPROTECTING | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0994108-A1 | PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330074-A1 | COMPOUNDS AND METHODS FOR TREATING SPASTICITY | SMN1; SMN2, MUSK, GAB1 | ANPEP 2262/4885ERAP1 1859/4885ERAP2 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.